BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Entezari M, Sadrkhanloo M, Rashidi M, Asnaf SE, Taheriazam A, Hashemi M, Ashrafizadeh M, Zarrabi A, Rabiee N, Hushmandi K, Mirzaei S, Sethi G. Non-coding RNAs and macrophage interaction in tumor progression. Crit Rev Oncol Hematol 2022;:103680. [PMID: 35405273 DOI: 10.1016/j.critrevonc.2022.103680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou X, Liu Q, Wang X, Yao X, Zhang B, Wu J, Sun C. Exosomal ncRNAs facilitate interactive ‘dialogue’ between tumor cells and tumor-associated macrophages. Cancer Letters 2023;552:215975. [DOI: 10.1016/j.canlet.2022.215975] [Reference Citation Analysis]
2 Wei F, Li Y. The emerging roles of exosome-derived noncoding RNAs in the tumor immune microenvironment and their future applications. Biomedicine & Pharmacotherapy 2022;156:113863. [DOI: 10.1016/j.biopha.2022.113863] [Reference Citation Analysis]
3 Tuli HS, Kaur J, Vashishth K, Sak K, Sharma U, Choudhary R, Behl T, Singh T, Sharma S, Saini AK, Dhama K, Varol M, Sethi G. Molecular mechanisms behind ROS regulation in cancer: A balancing act between augmented tumorigenesis and cell apoptosis. Arch Toxicol 2022. [DOI: 10.1007/s00204-022-03421-z] [Reference Citation Analysis]
4 Hashemi M, Hajimazdarany S, Mohan CD, Mohammadi M, Rezaei S, Olyaee Y, Goldoost Y, Ghorbani A, Mirmazloomi SR, Gholinia N, Kakavand A, Salimimoghadam S, Ertas YN, Rangappa KS, Taheriazam A, Entezari M. Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: Tumorigenesis, chemoresistance, and radioresistance. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106535] [Reference Citation Analysis]
5 Entezari M, Taheriazam A, Orouei S, Fallah S, Sanaei A, Hejazi ES, Kakavand A, Rezaei S, Heidari H, Behroozaghdam M, Daneshi S, Salimimoghadam S, Mirzaei S, Hashemi M, Samarghandian S. LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions. Biomed Pharmacother 2022;154:113609. [PMID: 36037786 DOI: 10.1016/j.biopha.2022.113609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tang S, Bai Y, Chen D, Wang Y, Zhang Y. Integrated single-cell and bulk RNA sequencing analysis revealing the role of FCGR2A on prognosis and immune infiltration of hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-1963438/v1] [Reference Citation Analysis]
7 Khatoon E, Parama D, Kumar A, Alqahtani MS, Abbas M, Girisa S, Sethi G, Kunnumakkara AB. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy. Life Sci 2022;:120827. [PMID: 35907493 DOI: 10.1016/j.lfs.2022.120827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]